BRAF V600
Aug 25, 2020
Novartis’s Spartalizumab Combo Stumbles; Union Therapeutics Doses In COVID-19 Trial; Yumanity To Merge With Proteostasis
Novartis’s Spartalizumab Combo Fails To Meet The Primary Goal In The Melanoma Trial Novartis recently declared the results of its Phase III COMBI-I trial evaluating its experimental checkpoint inhibitor spartalizumab in combination with Tafinlar (dabrafenib) and Mekinist (trametinib) for patients, previous...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
